PHASE I STUDY OF INTRAVESICAL VACCINIA VIRUS AS A VECTOR FOR GENE THERAPY OF BLADDER CANCER
- 1 October 2001
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 166 (4) , 1291-1295
- https://doi.org/10.1016/s0022-5347(05)65755-2
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Timing of cystectomy for superficial bladder tumorsUrologic Oncology: Seminars and Original Investigations, 2000
- MAINTENANCE BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY FOR RECURRENT TA, T1 AND CARCINOMA IN SITU TRANSITIONAL CELL CARCINOMA OF THE BLADDER: A RANDOMIZED SOUTHWEST ONCOLOGY GROUP STUDYJournal of Urology, 2000
- EFFICACY AND SAFETY OF VALRUBICIN FOR THE TREATMENT OF BACILLUS CALMETTE-GUERIN REFRACTORY CARCINOMA IN SITU OF THE BLADDERJournal of Urology, 2000
- Intravesical therapy for bladder cancerUrology, 2000
- Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanomaCancer Gene Therapy, 1999
- SUPERFICIAL BLADDER CANCER: THE ROLE OF INTERFERON-alphaJournal of Urology, 1998
- Immunohistochemical localization of p21WAF1/CIP1 in normal, hyperplastic, and neoplastic uterine tissuesHuman Pathology, 1997
- Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.Proceedings of the National Academy of Sciences, 1996
- Analysis of early failures after intravesical instillation therapy with bacille Calmette‐Guerin for carcinoma in situ of the bladderBritish Journal of Urology, 1995
- Risks and Benefits of Repeated Courses of Intravesical Bacillus Calmette-guerin Therapy for Superficial Bladder CancerJournal of Urology, 1987